Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study

Abstract

This pilot study suggests clinical and bacteriological advantages of continuous infusion of ceftriaxone over bolus administration in critically ill patients in patients requiring 4 or more days of treatment. This sets the scene for a large multicentre double-blind randomized controlled trial to confirm these findings.